US16934W1062 - Common Stock
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience
Chimerix files prospectus for $250M mixed shelf offering, however, it does not indicate an offer to sell.
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in...
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience...
Chimerix (CMRX) has promoted Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective Dec
Proven Leader Brings More Than 25 Years of Financial Experience
Proven Leader Brings More Than 25 Years of Financial Experience...
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of...
Chimerix appoints Thomas Riga as Chief Operating and Commercial Officer, enhancing their executive leadership team.
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development...
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively...
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS...
CMRX stock may seem like a high-risk, high-potential play, but it makes sense why the market has bid down this biotech.
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – –...
Although speculative trades are not for everyone, these millionaire-maker penny stocks could turn small bets into big returns.
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...
If you don’t mind the extreme risks involved, growth investors should target these ideas for best small cap stocks to buy.
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.
Biopharmaceutical company Chimerix (CMRX) said on Tuesday that Chief Business Officer and CFO Mike Andriole has been promoted to the post of president and CEO.